Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

Impact of C-arm CT in Patients With Decreased Renal Function Undergoing Transhepatic Arterial Chemoembolization (TACE) for the Treatment of Hepato-Cellular Carcinoma

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01326390

Enrollment

Registered

2011-03-30

Start date

2010-05-31

Completion date

2012-01-31

Last updated

2016-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney (Renal Cell) Cancer

Brief summary

Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.

Interventions

DEVICEdTA/dBA C-arm fluoroscopy system with Dyna CT

C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry

PROCEDUREDSA arteriogram- hepatic arteries

Standard of care

PROCEDURECO2 aortogram

Standard of care

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients must be affected by HCC 2. Patients must have diminished renal function (GFR\<60 ml/min/1.73m\^2) 3. Patients must be 18 years old or older 4. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure. 5. Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

1. Subjects under the age of 18 2. Patients currently on dialysis 3. Pregnant women

Design outcomes

Primary

Measure	Time frame
Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)	3 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026